Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulated Protein Degradation

Regulated Protein Degradation

Directing Proteins to the Rough Endoplasmic Reticulum

Directing Proteins to the Rough Endoplasmic Reticulum

The organelle-specific signaling sequences direct proteins synthesized in the cytosol to their final destination like ER, mitochondria, peroxisomes, etc. Some of the proteins directed to ER are then trafficked via vesicles to other organelles within the cell or the extracellular environment through the Golgi complex. For example, the rough ER synthesizes soluble proteins for transportation to the lysosomes or secretion out of the cell. It can also synthesize transmembrane proteins that can...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

Regulation of Expression at Multiple Steps

Regulation of Expression at Multiple Steps

The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...

Nonlinear Pharmacokinetics: Role of Transporters

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A mechanistic pharmacokinetic-pharmacodynamic model for degrader-antibody conjugates.

Journal of pharmacokinetics and pharmacodynamics·2026

Same author

A pharmacokinetic-pharmacodynamic/toxicodynamic model framework for PARP inhibitor combination therapy with DNA-damaging chemotherapeutics.

Cancer chemotherapy and pharmacology·2026

Same author

Dose Optimization of ClpP Agonists Using an In Vitro Microfluidic Perfusion Platform and In Silico Pharmacokinetic-Pharmacodynamic Modeling.

The AAPS journal·2025

Same author

An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes.

Nature chemical biology·2024

Same author

Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M<sub>4</sub> Muscarinic Acetylcholine Receptor.

Journal of medicinal chemistry·2024

Same author

Delivering on the promise of protein degraders.

Nature reviews. Drug discovery·2023

Search research articles

Related Experiment Video

Updated: Sep 26, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Translational PK-PD for targeted protein degradation.

Derek W Bartlett¹, Adam M Gilbert²

¹Pharmacokinetics, Dynamics, & Metabolism, Pfizer Worldwide Research, Development and Medical, Pfizer Inc, San Diego, CA, USA. Derek.Bartlett@pfizer.com.

Chemical Society Reviews

|April 19, 2022

Summary

Targeted protein degradation offers novel therapeutic potential. This review details pharmacokinetic (PK) and pharmacodynamic (PD) strategies for developing protein degrader drugs, providing a roadmap for efficient drug design.

More Related Videos

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Published on: April 18, 2016

Related Experiment Videos

Last Updated: Sep 26, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Published on: April 18, 2016

Area of Science:

Chemical biology
Pharmacology
Drug Development

Background:

Targeted protein degradation is a rapidly advancing field in therapeutic development.
Protein degraders offer advantages over inhibitors by inducing target protein removal.
Unique physicochemical and mechanistic properties necessitate specialized pharmacokinetic (PK) and pharmacodynamic (PD) considerations.

Purpose of the Study:

To provide practical insights into understanding the PK-PD of protein degraders.
To guide translational pharmacology for novel therapeutic development.
To establish a systematic workflow for protein degrader drug design.

Main Methods:

Utilizing quantitative mathematical frameworks for PK-PD analysis.
Employing standard experimental assays for pharmacological assessment.
Analyzing published datasets on protein degrader pharmacology.

Main Results:

Demonstrated applicability of PK-PD insights using real-world data.
Identified key considerations for translating preclinical findings to clinical applications.
Developed a comprehensive translational PK-PD roadmap.

Conclusions:

A systematic approach to PK-PD is crucial for successful protein degrader therapeutics.
The proposed roadmap facilitates rational design and development of targeted protein degraders.
This work aids the pharmaceutical industry in advancing novel protein degradation strategies.